MedPath

Clinical study on the treatment of qi stagnation and phlegm obstruction dyslipidemia with Jieyu Qutan Huazhuo prescriptio

Phase 1
Conditions
hypertriglyceridemia
Registration Number
ITMCTR2200005539
Lead Sponsor
Guang'anmen Hospital, China Academy of Chinese Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

(1) Aged between 18 and 80;
(2) Meet the diagnostic criteria of hypertriglyceridemia;
(3) Meet the diagnostic criteria of qi stagnation and phlegm obstruction syndrome;
(4) Those who are using other lipid-lowering drugs or therapies (including physical therapy) should stop taking the drugs or stop the therapy and still meet the above standards after 2 weeks of elution;
(5) Voluntarily join the study and sign the informed consent.

Exclusion Criteria

(1) Secondary hypertriglyceridemia caused by hypothyroidism, nephrotic syndrome, diabetes and other diseases;
(2) Have suffered from acute cardiovascular and cerebrovascular events or severe trauma within 1 year;
(3) Patients who need to take drugs with definite influence on triglyceride level for a long time after previous PCI or other major surgery;
(4) Patients suffering from systemic serious diseases of the heart, brain, liver, kidney and immune system, or mental patients;
(5) The patient is using drugs that affect lipid metabolism, such as glucocorticoids, thyroid hormones, and moderate potency diuretics
(6) The patient or his/her spouse is in the stage of pregnancy, pregnancy or lactation;
(7) People who may be allergic to the drug in this test;
(8) Other circumstances that may affect the efficacy and safety of the test drug.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Triglyceride levels;
Secondary Outcome Measures
NameTimeMethod
TCM syndrome score;
© Copyright 2025. All Rights Reserved by MedPath